Back to Journals » ClinicoEconomics and Outcomes Research » Volume 4

Cost considerations in the management of atrial fibrillation – impact of dronedarone

Authors Khaykin Y, Shamiss

Received 2 November 2011

Accepted for publication 28 December 2011

Published 6 March 2012 Volume 2012:4 Pages 67—78

DOI https://doi.org/10.2147/CEOR.S16675

Review by Single-blind

Peer reviewer comments 2

Yaariv Khaykin1,2, Yana Shamiss1
1Heart Rhythm Program, Southlake Regional Health Center, Newmarket, Ontario, Canada; 2Faculty of Medicine, University of Toronto, Ontario, Canada

Abstract: Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. It is associated with significant morbidity and mortality. At the societal level, AF carries an enormous cost. Strategies aimed at reducing AF morbidity and mortality and containing the associated fiscal burden are of paramount importance. This review will discuss AF treatment strategies and economics, focusing on the impact of dronedarone, a novel antiarrhythmic agent.

Keywords: antiarrhythmic, rhythm control, heart failure, ablation, costs

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]